Radiation-induced cell cycle delays and p53 status of early passage melanoma cell lines

Oncology Research

Volumn 12, Issue 3, 2000, Pages 149-155

  Parmar, Jayamala ^a,b   Marshall, Elaine S ^a   Charters, Geoffrey A ^a,b   Holdaway, Karen M ^a   Shelling, Andrew N ^b   Baguley, Bruce C ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

DNA sequencing; Flow cytometry; Melanoma; p53; Polymorphism; Radiation; Single strand conformation analysis (SSCP)

Indexed keywords

DNA; THYMIDINE;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL CYCLE; CHEMISTRY; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; MALE; MELANOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIATION EXPOSURE; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; GENES, P53; HUMANS; MALE; MELANOMA; MIDDLE AGED; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; THYMIDINE; TUMOR CELLS, CULTURED;

EID: 0034568512     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747620     Document Type: Article

References (36)

1. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science 253:49-53; 1991.
2. Kinzler, K. W.; Vogelstein, B. Life (and death) in a malignant tumour. Nature 379:19-20; 1996.
3. El-Deiry, W. S.; Harper, J. W.; O'Connor, P. M.; Velculescu, V. E.; Canman, C. E.; Jackman, J.; Pietenpol, J. A.; Burrell, M.; Hill, D. E.; Wang, Y. S.; Wiman, K. G.; Mercer, W. E.; Kastan, M. B.; Kohn, K. W.; Elledge, S. J.; Kinzler, K. W.; Vogelstein, B. Waf1/cipl is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54:1169-1174; 1994.
4. Brown, J. M.; Wouters, B. G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1391-1399; 1999.
5. Hill, L. L.; Ouhtit, A.; Loughlin, S. M.; Kripke, M. L.; Ananthaswamy, H. N.; Owen-Schaub, L. B. Fas ligand: A sensor for DNA damage critical in skin cancer etiology. Science 285:898-900; 1999.
6. Ziegler, A.; Leffell, D. J.; Kunala, S.; Sharma, H. W.; Gailani, M.; Simon, J. A.; Halperin, A. J.; Baden, H. P.; Shapiro, P. E.; Bale, A. E.; Brash, D. E. Mutation hotspots due to sunlight in the p53 gene of non-melanoma skin cancers. Proc. Natl. Acad. Sci. USA 90:4216-4220; 1993.
7. Jemal, A.; Devesa, S. S.; Fears, T. R.; Hartge, P. Cancer surveillance series: Changing patterns of cutaneous malignant melanoma mortality rates among whites in the United States. J. Natl. Cancer. Inst. 92:811-818; 2000.
8. Volkenandt, M.; Schlegel, U.; Nanus, D. M.; Albino, A. P. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell. Res. 4:35-40; 1991.
9. Weiss, J.; Schwechheimer, K.; Cavence, W. K.; Herlyn, M.; Arden, K. C. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer 54:693-699; 1993.
10. Florenes, V. A.; Oyjord, T.; Holm, R.; Skrede, M.; Borresen, A. L.; Nesland, J. M.; Fodstad, O. TP53 allele loss, mutations and expression in malignant melanoma. Br. J. Cancer 69:253-259; 1994.
11. Zerp, S. F.; van Elsas, A.; Peltenburg, L. T. C.; Schrier, P. I. p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br. J. Cancer 79:921-926; 1999.
12. Jones, W. O.; Harman, C. R.; Ng, A. K.; Shaw, J. H. Incidence of malignant melanoma in Auckland, New Zealand: Highest rates in the world. World J. Surg. 23:732-735; 1999.
13. McKenzie, R.; Conner, B.; Bodeker, G. Increased summertime UV radiation in New Zealand in response to ozone loss. Science 285:1709-1711; 1999.
14. Marshall, E. S.; Holdaway, K. M.; Shaw, J. H. F.; Finlay, G. J.; Matthews, J. H. L.; Baguley, B. C. Anticancer drug sensitivity profiles of new and established melanoma cell lines. Oncol. Res. 5:301-309; 1993.
15. 3H]-thymidine incorporation and soft agar clonogenic assays. Eur. J. Cancer 30A:1370-1376; 1994.
16. Hasegawa, H.; Ueda, M.; Furkawa, K.; Watanabe, M.; Teramoto, T.; Mukai, M.; Kitajima, M. p53 gene mutations in early colorectal carcinoma. De novo vs adenoma-carcinoma sequence. Int. J. Cancer 64:47-51; 1995.
17. Skilling, J. S.; Squatrito, R. C.; Connor, J. P.; Niemann, T.; Buller, R. E. p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol. Oncol. 60:72-80; 1996.
18. Angelopoulou, K.; Diamandis, E. P. Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis - application to breast and ovarian tumors. J. Clin. Lab. Anal. 12:250-256; 1998.
19. Birgander, R.; Sjalander, A.; Rannug, A.; Alexandrie, A. K.; Sundberg, M. I.; Seidegard, J.; Tornling, G.; Beckman, G.; Beckman, L. p53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16:2233-2236; 1995.
20. O'Connor, P. M.; Jackman, J.; Jondle, D.; Bhatia, K.; Magrath, I.; Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res. 53:4776-4780; 1993.
21. Baguley, B. C.; Marshall, E. S.; Whittaker, J. R.; Dotchin, M. C.; Nixon, J.; McCrystal, M. R.; Finlay, G. J.; Matthews, J. H. L.; Holdaway, K. M.; van Zijl, P. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur. J. Cancer 31A:230-237; 1995.
22. Nylander, K.; Bourdon, J. C.; Bray, S. E.; Gibbs, N. K.; Kay, R.; Hart, I.; Hall, P. A. Transcriptional activation of tyrosinase and TRP-I by p53 links UV irradiation to the protective tanning response. J. Pathol. 190:39-46; 2000.
23. Formenti, S. C.; Dunnington, G.; Uzieli, B.; Lenz, H.; Kerenrosenberg, S.; Silberman, H.; Spicer, D.; Denk, M.; Leichman, G.; Groshen, S.; Watkins, K.; Muggia, F.; Florentine, B.; Press, M.; Danenberg, K.; Danenberg, P. Original p53 status predicts for pathological response in locally advanced breast cancer patients treated preoperatively with continuous infusion 5-fluorouracil and radiation therapy. Int. J. Rad. Oncol. Biol. Phys. 39:1059-1068; 1997.
24. Hansson, J. Systemic therapy of malignant melanoma. Med. Oncol. 14:73-81; 1997.
25. Bae, I.; Smith, M. L.; Sheikh, M. S.; Zhan, Q. M.; Scudiero, D. A.; Friend, S. H.; O'Connor, P. M.; Fornace, A. J. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines. Cancer Res. 56:840-847; 1996.
26. Trotter, M. J.; Tang, L. R.; Tron, V. A. Overexpression of the cyclin-dependent kinase inhibitor p21(waf1/cip1) in human cutaneous malignant melanoma. J. Cutan. Pathol. 24:265-271; 1997.
27. Rieber, M.; Strasberg Rieber, M. Apoptosis-inducing levels of UV radiation and proteasome inhibitors produce opposite effects on p21 (WAF1) in human melanoma cells. Int. J. Cancer 86:462-467; 2000.
28. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. MDM2 promotes the rapid degradation of p53. Nature 387:296-299; 1997.
29. Zhang, Y. P.; Xiong, Y.; Yarbrough, W. G. ARF promotes mdm2 degradation and stabilizes p53-ARF-INK4A locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734; 1998.
30. Liggett, W. H.; Sidransky, D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 16:1197-1206; 1998.
31. Stott, F. J.; Bates, S.; James, M. C.; McConnell, B. B.; Starborg, M.; Brookes, S.; Palmero, I.; Ryan, K.; Hara, E.; Vousden, K. H.; Peters, G. The alternative product from the human CDKN2a locus, p14(ARF), participates in a regulatory feedback loop with p53 and mdm2. EMBO J. 17:5001-5014; 1998.
32. Furnari, B.; Rhind, N.; Russell, P. Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. Science 277:1495-1497; 1997.
33. Lopez-Girona, A.; Furnari, B.; Mondesert, O.; Russell, P. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397:172-175; 1999.
34. Wang, J. Y. J. New link in a web of human genes. Nature 405: 404-405; 2000.
35. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J. P.; Sedivy, J. M.; Kinzler, K. W.; Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501; 1998.
36. Chan, T. A.; Hermeking, H.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B. 14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401:616-620; 1999.